Kura Oncology to Participate in Upcoming Investor Conference
Wednesday, September 24, 2025 1 min read
Key Takeaway: Kura Oncology, a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, will participate in the UBS Virtual Oncology Day on October 1, 2025. The event will include a live audio webcast available on the company's website, offering an archived replay for later access. This participation aims to enhance investor engagement and showcase the company's initiatives.
Market Sentiment Analysis
POSITIVE FACTORS
Kura Oncology is committed to advancing precision medicines for cancer.
Participation in investor conference highlights company engagement with stakeholders.
Opportunities for increased visibility and investment interest in the company.
Full Press Release Details
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following investor conference.
UBS Virtual Oncology Day
Wednesday, October 1, 2025
2:30 p.m. ET / 11:30 a.m. PT
A live audio webcast will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with an archived replay available following the event.